- Suppliers
ADM 
Armor Pharma 
Asahi KASEI 
Ashland 
BASF 
Beneo 
Captisol 
Clariant 
Croda 
DFE Pharma 
Excipio Chemicals 
Fuji Chemical 
Gattefossé 
Gangwal 
IamFluidics 
IOI Oleo 
Ingredient Pharm 
JRS Pharma 
Kerry 
KLK Oleo 
Lipoid 
Lubrizol Life Science Health 
MAGNESIA 
MEGGLE 
Nagase Viita 
Nordic Bioproducts 
Pfanstiehl 
pharm-a-spheres 
PMC Isochem 
Seppic 
ShinEtsu 
Sigachi 
SPI Pharma 
Südzucker 
Vikram Thermo 
Zerion Pharma 
All4Nutra
- Suppliers
ADM Armor Pharma Asahi KASEI Ashland BASF Beneo Captisol Clariant Croda DFE Pharma Excipio Chemicals Fuji Chemical Gattefossé Gangwal IamFluidics IOI Oleo Ingredient Pharm JRS Pharma Kerry KLK Oleo Lipoid Lubrizol Life Science Health MAGNESIA MEGGLE Nagase Viita Nordic Bioproducts Pfanstiehl pharm-a-spheres PMC Isochem Seppic ShinEtsu Sigachi SPI Pharma Südzucker Vikram Thermo Zerion Pharma - All4Nutra
Efficient delivery of abciximab using mesoporous silica nanoparticles: in-vitro assessment for targeted and improved antithrombotic activity
Efficient-delivery-of-abciximab-using-mesoporous-silica-nanoparticles-in-vitro-assessment-for-targeted-and-improved-antithrombotic-activity
Abciximab (ABX) is a chimeric monoclonal antibody reported for antithrombotic activity but their delivery remains challenging due to its poor stability in a biological system. The purpose of this research was to deliver ABX on the target efficiently using mesoporous silica nanoparticles (MSN). ABX coated mesoporous silica nanoparticles (MSN-ABX) were formulated and analyzed for particle size, shape, zeta-potential, surface morphology and surface chemistry. XPS analysis confirmed the presence of ABX on the surface of amino functionalized mesoporous silica nanoparticles (MSN-NH2). The degree of ABX attachment was 67.53±5.81% which was demonstrated by the Bradford assay.
Highlights
- A novel delivery system of abciximab coated mesoporous silica nanoparticles (MSN-ABX) were fabricated
- MSN-ABX exhibits a significant ABX loading required for therapeutic activity and sustained release profile
- The in-vitro assessment and imaging studies confirms the considerable affinity of MSN-ABX towards activated platelets
- The mesoporous silica nanoparticle shows great potential for efficient delivery of abciximab
Furthermore, the targeting efficiency of the targeted nanoparticles has been evaluated by capturing the fluorescent images in-vitro which showed the significant accumulation of the ABX coated nanoparticles towards activated platelets. The significant (P<0.05) increase in affinity of DiD dye loaded nanoparticles towards the activated platelets was confirmed by using an in-vitro imaging through photon imager optima. The hemolysis study of the nanoparticle formulations revealed that they were non-hemolytic for healthy human blood. The in-vitro antithrombotic effects of MSN-ABX were observed by blood clot assay which revealed its superior antithrombotic activity over clinical injection of ABX and could be a promising carrier for improved ABX targeted delivery.
Vishnu Priya, Vikas, Abhishesh Kumar Mehata, Dharmendra Jain, Sanjeev Kumar Singh, Madaswamy S. Muthu,
Efficient delivery of abciximab using mesoporous silica nanoparticles: in-vitro assessment for targeted and improved antithrombotic activity, Colloids and Surfaces B: Biointerfaces, 2022, 112697, ISSN 0927-7765,
https://doi.org/10.1016/j.colsurfb.2022.112697.
Related Posts
